False equivalence.
The insinuation is that RAC strategically canned RC110 the moment RC220 was developed to better spend capital elsewhere, resulting in schedule blow-outs.
That's not the case.
According to RAC's own announcements, RC110 should have been dosed in EML AND BC patients, in a low dose setting, with the aim of therapeutically validating Zan as an FTO inhibitor PRIOR to FY23. RC220 wasn't announced until Q2 FY23.
RAC couldn't get there. This validation would have been immensely valuable and the company wouldn't be raising cash at a pittance today. If we're throwing around our preferred scenarios then this is my nomination.
- Forums
- ASX - By Stock
- RAC
- RAC - Charts & Price Action
RAC - Charts & Price Action, page-18421
-
-
- There are more pages in this discussion • 3,141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.80 |
Change
0.045(2.57%) |
Mkt cap ! $302.3M |
Open | High | Low | Value | Volume |
$1.82 | $1.82 | $1.78 | $39.09K | 21.84K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5617 | $1.78 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.80 | 3199 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5617 | 1.780 |
2 | 1255 | 1.775 |
2 | 2104 | 1.770 |
1 | 605 | 1.765 |
2 | 619 | 1.755 |
Price($) | Vol. | No. |
---|---|---|
1.795 | 3199 | 3 |
1.800 | 3111 | 3 |
1.805 | 2215 | 2 |
1.815 | 248 | 1 |
1.820 | 215 | 1 |
Last trade - 11.47am 10/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online